Skip to main content
. 2015 Jun 22;125(7):2795–2807. doi: 10.1172/JCI77958

Figure 3. Changes in biomarker gene expression and MRSS by study group.

Figure 3

(A and B) THBS1 and (C and D) COMP gene expression and (E and F) MRSS from study patients in (A, C, and E) group 1 (n = 7), which received 2 doses of 1 mg/kg fresolimumab, and (B, D, and F) group 2 (n = 8), which received 1 dose of 5 mg/kg fresolimumab. Dot plots show median (horizontal bars) and statistical significance of THBS1 and COMP gene expression (Wilcoxon signed-rank test, using available data). Box plots show median (horizontal line), interquartile (box), and 95% confidence limits (whiskers) of MRSS. Line graphs showing changes in individual patients over time are shown in Supplemental Figure 1.